News for Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics (AVTX) has received a positive boost in its stock prospects, following an announcement by HC Wainwright & Co. The firm, represented by analys

H.C. Wainwright analyst Mitchell Kapoor has initiated coverage on Avalo Therapeutics (AVTX), assigning a Buy rating and setting a target price of $15. Avalo The

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ( AVTX), a clinical stage biotechnology company focused on the treatm

Avalo Therapeutics (AVTX) is set to participate in two major investor conferences in June 2025. The company will engage in a fireside chat at the Jefferies

As of March 31, 2025, AVTX reported cash and cash equivalents totaling $125 million. During the first quarter of 2025, the company used $9.5 million in net cash

AVTX is making significant headway in its Phase 2 LOTUS trial focusing on hidradenitis suppurativa. The trial's progress, including site activations, screenings

Strong cash position of $125M providing runway into 2027, with optionality to extend to 2028. Phase 2 LOTUS trial enrollment progressing on schedule; to

Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 20

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ( AVTX), a clinical stage biotechnology company focused on the trea

A range of new options have been listed for trading beginning April 16th, featuring notable companies and ETFs. Among these, Avalo Therapeutics (AVTX) stands ou

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Offi

Discover Avalo Therapeutics' (AVTX) FY financial results: GAAP EPS of -$20.91, revenue down 77.1% YoY to $0.44M.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[548326]**

WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ( AVTX), a clinical stage biotechnology company focused on the treat

Avalo Therapeutics (AVTX) stock surges as Wedbush initiates with a bullish view, citing lead asset AVTX-009's potential against hidradenitis suppurativa. Read more here.

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a strategic transaction by acquiring an additional 71,243 shares of Avalo Therap

**media[531691]**